



ERRATUM

Erratum to ‘Efficacy and correlative analyses of avelumab plus axitinib versus sunitinib in sarcomatoid renal cell carcinoma: *post hoc* analysis of a randomized clinical trial’

[ESMO Open Volume 6, Issue 3, June 2021, 100101]

T. K. Choueiri^{1*}, J. Larkin², S. Pal³, R. J. Motzer⁴, B. I. Rini⁵, B. Venugopal⁶, B. Alekseev⁷, H. Miyake⁸, G. Gravis⁹, M. A. Bilen¹⁰, S. Hariharan¹¹, A. Chudnovsky¹², K. A. Ching¹³, X. J. Mu¹³, M. Mariani¹⁴, P. B. Robbins¹⁵, B. Huang¹⁶, A. di Pietro¹⁴ & L. Albiges¹⁷

¹Department of Medical Oncology, The Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute and Brigham and Women’s Hospital, Boston, USA; ²Renal and Skin Units, The Royal Marsden NHS Foundation Trust, Chelsea, London, UK; ³Department of Medical Oncology, City of Hope Comprehensive Cancer Center, Duarte;

⁴Department of Medicine, Memorial Sloan Kettering Cancer Center, New York; ⁵Department of Medicine, Division of Hematology and Oncology, Vanderbilt University Medical Center, Nashville, USA; ⁶Institute of Cancer Sciences, University of Glasgow, Beatson West of Scotland Cancer Centre, Glasgow, Scotland, UK; ⁷P. Hertsen Moscow Oncology Research Institute, Moscow, Russia; ⁸Department of Urology, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan;

⁹Department of Medical Oncology, Institut Paoli-Calmettes, Aix-Marseille Université, Inserm, CNRS, CRCM, Marseille, France; ¹⁰Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta; ¹¹Oncology, Pfizer, New York; ¹²Oncology, Pfizer, Cambridge; ¹³Computational Biology, Pfizer, San Diego, USA; ¹⁴Immuno-Oncology, Pfizer, Milan, Lombardia, Italy; ¹⁵Translational Oncology, Pfizer, San Diego; ¹⁶Biostatistics, Pfizer, Groton, USA; ¹⁷Department of Medical Oncology, Institut Gustave Roussy, Villejuif, France


The publisher regrets that some minor corrections to punctuation were missed in the typesetting process. In addition, Figure 3C was incorrect when the article was published. All corrections have now been applied to the article and the figure corrected. The corrected Figure 3C also appears below:

DOI of original article: <https://doi.org/10.1016/j.esmoop.2021.100101>

*Correspondence to: T. K. Choueiri.

E-mail: toni_choueiri@dfci.harvard.edu (T. K. Choueiri).

2059-7029/© 2021 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).



The publisher would like to apologise for any inconvenience caused.